Oncolytics Biotech Inc. Files June 2025 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
TL;DR
ONCOLYTICS BIOTECH INC. filed their June 2025 6-K, confirming foreign private issuer status and 20-F filing.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on June 30, 2025, reporting for the month of June 2025. The company, based in Calgary, Alberta, Canada, is a foreign private issuer and is filing under the 1934 Securities Exchange Act. They are submitting this report as a foreign private issuer and will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and stakeholders regarding the company's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain material new financial information or significant operational changes.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- June 2025 (date) — Reporting period
- Calgary, Alberta, Canada (location) — Company headquarters
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report for the month of June 2025 as a foreign private issuer and to confirm the company's intention to file annual reports under Form 20-F.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located in Calgary, Alberta, Canada.
Under which act is this filing made?
This filing is made pursuant to the 1934 Securities Exchange Act.
Does Oncolytics Biotech Inc. file annual reports as Form 40-F?
No, the filing indicates that Oncolytics Biotech Inc. files annual reports under Form 20-F, not Form 40-F.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).